Home Cart Sign in  
Chemical Structure| 137076-22-3 Chemical Structure| 137076-22-3

Structure of 137076-22-3

Chemical Structure| 137076-22-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 137076-22-3 ]

CAS No. :137076-22-3
Formula : C11H19NO3
M.W : 213.27
SMILES Code : O=C(N1CCC(C=O)CC1)OC(C)(C)C
MDL No. :MFCD02179019
InChI Key :JYUQEWCJWDGCRX-UHFFFAOYSA-N
Pubchem ID :1514430

Safety of [ 137076-22-3 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P362+P364-P403+P233-P501

Computational Chemistry of [ 137076-22-3 ] Show Less

Physicochemical Properties

Num. heavy atoms 15
Num. arom. heavy atoms 0
Fraction Csp3 0.82
Num. rotatable bonds 4
Num. H-bond acceptors 3.0
Num. H-bond donors 0.0
Molar Refractivity 61.6
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

46.61 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.4
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.07
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.45
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.05
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.24
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.44

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.57
Solubility 5.71 mg/ml ; 0.0268 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.64
Solubility 4.88 mg/ml ; 0.0229 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.23
Solubility 12.6 mg/ml ; 0.059 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.84 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.01

Application In Synthesis of [ 137076-22-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 137076-22-3 ]

[ 137076-22-3 ] Synthesis Path-Downstream   1~11

  • 1
  • [ 4138-26-5 ]
  • [ 137076-22-3 ]
  • [ 340962-96-1 ]
  • 2
  • [ 137076-22-3 ]
  • [ 154775-43-6 ]
  • 3
  • [ 137076-22-3 ]
  • [ 162504-75-8 ]
  • 4
  • [ 19493-09-5 ]
  • [ 137076-22-3 ]
  • [ 180307-56-6 ]
YieldReaction ConditionsOperation in experiment
In tetrahydrofuran; hexanes; at -78 - 20℃; for 0.5h; To a suspension of methyltriphenylphosphonium bromide (1.76 g, 4.93 mmol) in THF (30 ml), cooled to -78 C., was added n-BuLi (1.88 ml of 2.5M soln. in hexanes; 4.68 mmol), and the mixture was stirred at -78 C. for 30 min and then at 0 C. for 45 min. It was cooled back to -78 C., and a solution of aldehyde 6 (0.50 g, 2.34 mmol) in THF (5 ml) was added. The reaction mixture was stirred at -78 C. for 30 min and warmed up to rt. It was quenched with water, and the product was extracted with CH2Cl2. The organic layer was dried over Na2SO4 and purified by flash chromatography (0.5% MeOH/CH2Cl2) to provide 0.24 g of 20 as a clear oil. Step 2: BOC-deprotection and amide coupling steps as described in Example 2 were used to obtain the title compound MS (M+H): 347.
  • 5
  • [ 187669-60-9 ]
  • [ 137076-22-3 ]
  • 4-[4-(4-methanesulfonylphenyl)piperazin-1-ylmethyl]piperidine-1-carboxylic acid tert-butyl ester [ No CAS ]
YieldReaction ConditionsOperation in experiment
With sodium tris(acetoxy)borohydride; In dichloromethane; at 20℃; for 17h; Example 1; 4-[4-(4-Mcthancsulfonylphcnyl)pipcrazin-l -ylmcthyljpipcridinc-l -carboxylic acid tert-butyl ester; EPO <DP n="23"/>To a solution of l-(4-methanesulfonylphenyl)piperazine (0.41 mmol) and 4- formylpiperidine-1-carboxylic acid tert-mty ester (1.2 mmol) in DCM (3 mL) was added sodium triacetoxyborohydride (0.53 mmol). The resulting suspension was stirred at rt for 17 h. Polymer-supported isocyante scavenger resin (MP-NCO) (0.29 g, 1.44 mmol/g) was added and shaking continued until LCMS showed complete consumption of starting amine. The mixture was diluted with further DCM, shaken with water, and the organic layer separated using a hydrophobic frit. The crude mixture was purified via ion-exchange using an SCX column, to afford the title compound. deltaH (400 MHz, CHCl3) 1.14 (2H, m), 1.50 (9H, s), 1.70 (IH, m), 1.79 (2H, m), 2.26 (2H, d), 2.58 (4H, t), 2.74 (2H, m), 3.04 (3H, s), 3.38 (4H, t), 4.14 (2H, m), 6.96 (2H, d), 7.80 (2H, d).
  • 6
  • [ 30413-58-2 ]
  • [ 124-40-3 ]
  • [ 137076-22-3 ]
  • [ 1107617-19-5 ]
YieldReaction ConditionsOperation in experiment
With copper(l) iodide; In water; for 2h;Sonographic reaction; A mixture of <strong>[30413-58-2]2-ethynyl-6-methyl-pyridine</strong> (0.08 g, 0.7 mmol), 1-Boc-4-piperidinecarboxaldehyde (0.1 g, 0.47 mmol), CuI (0.001 g, 0.11 mmol) and 33% w/w aqueous dimethylamine (0.077 mL, 0.56 mmol) in water (3 mL) was sonicated for 2 h in a laboratory ultrasonic bath. Afterwards, it was extracted with EtOAc and the combined organic layers were washed with brine, dried on Na2SO4 and evaporated to dryness in vacuo to give a crude, which was purified by automated flash liquid chromatography (Horizon-Biotage) eluting with EtOAc-Petroleum Ether 1:1 affording the title product (0.11 g).1H-NMR (CDCl3, delta): 1.25-1.48 (m, 2H), 1.51 (s, 9H), 1.65-1.73 (m, 1H), 2.05-2.11 (m, 2H), 2.23-2.40 (br, 6H), 2.66 (s, 3H), 2.69-2.77 (m, 2H), 3.21-3.39 (m, 1H), 4.09-4.21 (m, 2H), 7.09-7.11 (m, 1H), 7.27-7.30 (m, 1H), 7.53-7.56 (m, 1H).MS: [M+H]+=358.6
  • 7
  • [ 30413-58-2 ]
  • [ 137076-22-3 ]
  • [ 1107617-18-4 ]
YieldReaction ConditionsOperation in experiment
A mixture of zinc trifluoromethanesulfonate (0.07 g, 0.19 mmol) and triethylamine (0.065 mL, 0.47 mmol) in anhydrous toluene (5 mL) was stirred at room temperature under nitrogen atmosphere. After 1 h, <strong>[30413-58-2]2-ethynyl-6-methyl-pyridine</strong> (0.13 g, 1.13 mmol) prepared as described in WO200544267 was added and after 15 min was dropped a solution of 1-Boc-4-piperidinecarboxaldehyde (0.2 g, 0.938 mmol) in toluene (1 mL): the resulting mixture was heated at 100 C. for 6 h. Afterwards, it was cooled to r.t., diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried on Na2SO4 and evaporated to dryness in vacuo to give a crude, which was purified twice by automated flash liquid chromatography (Horizon-Biotage) eluting with CHCl3-MeOH 98-2 affording the title product (0.13 g) as a brown oil.1H-NMR (CDCl3, delta): 1.27-1.5 (m, 12H), 1.85-2.01 (m, 3H), 2.63 (s, 3H), 2.65-2.82 (m, 2H) 4.15-4.31 (m, 2H), 4.44-4.49 (m, 1H), 7.15-7.18 (m, 1H), 7.27-7.30 (m, 1H), 7.61-7.65 (m, 1H).MS: [M+H]+=331.6
  • 8
  • [ 75-16-1 ]
  • [ 137076-22-3 ]
  • [ 183170-69-6 ]
YieldReaction ConditionsOperation in experiment
97.7% In tetrahydrofuran; at 0 - 20℃; for 1h; To a stirred solution of t-butyl 4-formylpiperidine-1-carboxylate (0.5 g, 2.34 mmol) in THF (10 mL) was added MeMgBr (1.5M in THF) (3 mL, 4.68 mmol at 0 C. and reaction allowed to stir at room temperature for 1 h. Reaction was monitored by TLC. Reaction was quenched with aq. NH4Cl, extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulphate and concentrated under reduced pressure to give 525 mg (97.7%) of t-butyl 4-(1-hydroxyethyl)piperidine-1-carboxylate. MS: 230.2[M++1]
Preparation 4; 4-(1-Methanesulfonyloxy-ethyl)-piperidine-1-carboxylic acid tert-butyl ester1: 4-(1-Hydroxy-ethyl)-piperidine-1-carboxylic acid tert-butyl esterTo a solution of N-tert-butoxycarbonyl-4-piperidinecarboxaldehyde (32.20 g, 151.45 mmol) in tetrahydrofuran at -78 C. is added methyl magnesium bromide (2 M in diethyl ether, 100.96 mL, 302.89 mmol). The reaction is stirred at -78 C. for 4.5 h, and then warmed to -50 C. for 30 min. The reaction is quenched with water at -50 C. and allowed to warm to room temperature for 16 h. The solvents are removed and the material is partitioned between diethyl ether and 0.1 M hydrochloric acid. The mixture is extracted with diethyl ether. The combined organic layers are washed with 0.1 M hydrochloric acid, saturated aqueous sodium bicarbonate and brine, dried over magnesium sulfate, filtered, and concentrated to dryness. The crude is purified by flash chromatography over silica gel to afford 16.90 g of the title compound as a colourless oil. MS (m/z) 229 (M+1).
  • 10
  • [ 638-94-8 ]
  • [ 137076-22-3 ]
  • (1S,2S,4R,6R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-(piperidin-4-yl)-5,7-dioxapentacyclo[10.8.0.0<SUP>2</SUP>'<SUP>9</SUP>.0<SUP>4</SUP>'<SUP>8</SUP>.0<SUP>13</SUP>'<SUP>18</SUP>]icosa-14,17-dien-16-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
13% With perchloric acid; In water; at 0 - 20℃; This example demonstrates a method for making compound 7-4R in Table 1. This example refers to the compound numbering in FIG. 1. (1S,2S,4R,6R,8S,9S, 11S,12S, 13R)-1 l-Hydroxy-8-(2-hydroxyacetyl)-9, 13- dimethyl-6-(piperidin- -yl)-5,7-dioxapentacyclo[10.8.0.002'9.04'8.01 '18]icosa-14,17-dien- 16-one (7-4R). [0527] To a solution of <strong>[638-94-8]desonide</strong> (1, 0.10 g, 0.25 mmol) in nitropropane (5 mL) was added aqueous perchloric acid (70%, 0.11 g, 0.75 mmol) dropwise at 0 C, followed by the addition of l-Boc- -piperidinecarboxaldehyde (4-4, 64 mg, 0.30 mmol). After being stirred at RT overnight, the suspension was concentrated in vacuo. The residue was basified by the addition of ammonia solution in methanol (7 M, 10 mL). The resulting mixture was concentrated in vacuo and the crude product was purified by prep-HPLC twice (method B) to yield compound 7-4R (15 mg, yield 13%) as a white solid. ESI m/z: 472 (M + H)+. MR (MeOD^, 500 MHz) delta 7 '.47 (d, J = 10.0 Hz, 1H), 6.27 (dd, J= 10.0 Hz, 2.0 Hz, 1H), 6.03 (s, 1H), 4.90 (d, J= 4.0 Hz, 1H), 4.50 (d, J = 19.0 Hz, 1H), 4.46-4.43 (m, 1H), 4.41 (d, J= 4.0 Hz, 1H), 4.29 (d, J= 19.0 Hz, 1H), 3.13-3.09 (m, 2H), 2.71-2.60 (m, 3H), 2.42-2.38 (m, 1H), 2.27-2.13 (m, 2H), 1.99-1.96 (m, 1H), 1.85-1.64 (m, 7H), 1.52 (s, 3H), 1.51-1.38 (m, 2H), 1.14-0.99 (m, 2H), 0.96 (s, 3H) ppm. The stereochemical R-configuration for compound 7-4R was determined by 2D NMR
  • 11
  • [ 67808-64-4 ]
  • [ 100-63-0 ]
  • [ 137076-22-3 ]
  • tert-butyl 1-((5-(methoxycarbonyl)thiophen-2-yl)methyl)spiro[indoline-3,4'-piperidine]-1'-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
30% General procedure: To a solution of cyclohexanecarboxyaldehyde 6a (0.224 mL, 1.85 mmol) in acetic acid (6 mL) phenylhydrazine (7) was added (0.182 mL, 1.85 mmol) and the reaction mixture was then heated to 80 °C for 2 h. Then methyl 4-formylbenzoate 8a (0.359 g, 1.85 mmol) in 1,2-DCE (6 mL) was added at 0 °C and after 15 min NaBH(OAc)3 (0.943 g, 4.25 mmol) was added portionwise. Reaction mixture was stirred at 25 °C for 12 h. Solvents were removed under reduced pressure, residue was diluted with 10 mL of EtOAc and washed with a saturated solution of Na2CO3. The combined organic phases were dried (Na2SO4) and concentrated in vacuo. Purification by column chromatography on silica gel (EtOAc/n-hexane 1:20) afforded the title compound as a yellow oil (yield 16percent).
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 137076-22-3 ]

Aldehydes

Chemical Structure| 189442-92-0

A180881 [189442-92-0]

1-Boc-4-Formyl-4-methylpiperidine

Similarity: 1.00

Chemical Structure| 142374-19-4

A121901 [142374-19-4]

tert-Butyl 4-(2-oxoethyl)piperidine-1-carboxylate

Similarity: 0.98

Chemical Structure| 118156-93-7

A265676 [118156-93-7]

tert-Butyl 3-formylpiperidine-1-carboxylate

Similarity: 0.96

Chemical Structure| 59379-02-1

A265540 [59379-02-1]

tert-Butyl 3-formylpyrrolidine-1-carboxylate

Similarity: 0.90

Chemical Structure| 157634-02-1

A218570 [157634-02-1]

tert-Butyl 2-formylpiperidine-1-carboxylate

Similarity: 0.87

Amides

Chemical Structure| 189442-92-0

A180881 [189442-92-0]

1-Boc-4-Formyl-4-methylpiperidine

Similarity: 1.00

Chemical Structure| 142374-19-4

A121901 [142374-19-4]

tert-Butyl 4-(2-oxoethyl)piperidine-1-carboxylate

Similarity: 0.98

Chemical Structure| 118156-93-7

A265676 [118156-93-7]

tert-Butyl 3-formylpiperidine-1-carboxylate

Similarity: 0.96

Chemical Structure| 206989-61-9

A298596 [206989-61-9]

tert-Butyl 4-acetylpiperidine-1-carboxylate

Similarity: 0.96

Chemical Structure| 419571-73-6

A753306 [419571-73-6]

tert-Butyl 4-propionylpiperidine-1-carboxylate

Similarity: 0.96

Related Parent Nucleus of
[ 137076-22-3 ]

Piperidines

Chemical Structure| 189442-92-0

A180881 [189442-92-0]

1-Boc-4-Formyl-4-methylpiperidine

Similarity: 1.00

Chemical Structure| 142374-19-4

A121901 [142374-19-4]

tert-Butyl 4-(2-oxoethyl)piperidine-1-carboxylate

Similarity: 0.98

Chemical Structure| 118156-93-7

A265676 [118156-93-7]

tert-Butyl 3-formylpiperidine-1-carboxylate

Similarity: 0.96

Chemical Structure| 206989-61-9

A298596 [206989-61-9]

tert-Butyl 4-acetylpiperidine-1-carboxylate

Similarity: 0.96

Chemical Structure| 419571-73-6

A753306 [419571-73-6]

tert-Butyl 4-propionylpiperidine-1-carboxylate

Similarity: 0.96